Showing results (181-190 of 194) with videos related to
Sort By:
Pageof 20
Cancer Immunology Research|April 16, 2017
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLCPaul C Tumeh, Matthew D Hellmann, Omid Hamid, et al.Cell|October 16, 2020
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerPatrick A Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, et al.Cancer Discovery|March 5, 2026
Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 resultsJie Deng, Aastha Pal, Stefano Testa, et al.Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In OncologySusan M Swetter, Douglas Johnson, Mark R Albertini, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2022
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134Michael B Atkins, Sandra J Lee, Bartosz Chmielowski, et al.The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.The New England Journal of Medicine|January 20, 2012
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitorsFei Su, Amaya Viros, Carla Milagre, et al.Nature|November 10, 2022
Non-viral precision T cell receptor replacement for personalized cell therapySusan P Foy, Kyle Jacoby, Daniela A Bota, et al.Pageof 20